Markers help to predict dementia with Lewy bodies.

Nat Rev Neurol

Nature Reviews Neurology, .

Published: January 2025

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-025-01058-xDOI Listing

Publication Analysis

Top Keywords

markers help
4
help predict
4
predict dementia
4
dementia lewy
4
lewy bodies
4
markers
1
predict
1
dementia
1
lewy
1
bodies
1

Similar Publications

Background: A right adrenal gland may present in the form of adreno-hepatic fusion (AHF), in which the adrenal cells are interspersed among the hepatocytes without septation. This rare, naturally-occurring phenomenon may be associated with preoperative misdiagnosis. We present two cases of adrenal tumor in patients with AHF that were misdiagnosed, despite thorough preoperative work-ups.

View Article and Find Full Text PDF

Background: To date, the overall survival (OS) of hormone receptor-positive advanced breast cancer (ABC) treated with palbociclib has not been reported in Chinese patients. It still remains unclear what kind of patients may benefit in OS from palbociclib treatment and what the optimal sequential antineoplastic regimen is for those progressing on palbociclib. Therefore, we aimed to investigate the OS outcome of ABC patients receiving palbociclib, establish a predictive model to identify the potential candidates who may benefit from palbociclib and explore the ideal subsequent treatment strategy after palbociclib.

View Article and Find Full Text PDF

The discrepancy between donor organ availability and demand leads to a significant waiting-list dropout rate and mortality. Although quantitative tools such as the Donor Risk Index (DRI) help assess organ suitability, many potentially viable organs are still discarded due to the lack of universally accepted markers to predict post-transplant outcomes. Normothermic machine perfusion (NMP) offers a platform to assess viability before transplantation.

View Article and Find Full Text PDF

CDK4/6 Inhibitor Resistance in ER+ Breast Cancer.

Adv Exp Med Biol

January 2025

Translational Research Unit, Hospital of Prato, AUSL Toscana Centro, Prato, Italy.

The cyclin-dependent kinases 4 and 6 inhibitors are the mainstay of treatment for patients with hormone receptor-positive and HER2-negative breast cancer. The ability of these drugs to improve the outcome of patients both in the metastatic and the early setting has been largely demonstrated. However, resistance, either de novo or acquired, represents a major clinical challenge.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!